Brief: Shenzhen Hepalink Pharmaceutical's Unit, Supplier To Produce Novonox Obtained Marketing Approval In Bolivia
07/06/2021 11:19
June 7 (Reuters) - Shenzhen Hepalink Pharmaceutical Group Co
Ltd 002399.SZ :
* UNIT, A SUPPLIER TO PRODUCE NOVONOX OBTAINED MARKETING
APPROVAL
FROM NATIONAL PHARMACOLOGICAL COMMISSION OF BOLIVIA
Source text for Eikon: ID:nHKSsjyB7
Further company coverage: 002399.SZ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shenzhen Hepalink Pharmaceutical Co
See all newsBrief: Shenzhen Hepalink Pharmaceutical Group Says Enoxaparin Sodium Injection Obtains New Manufacturer Authorization From EMA
Brief: Shenzhen Hepalink Pharmaceutical Group Posts QTRLY Net Profit Attributable Of RMB156.6 Million
Brief: Shenzhen Hepalink Pharmaceutical Posts Profit Attributable RMB646.7 Million For Year
Brief: Shenzhen Hepalink Pharmaceutical Says Enoparin Approved In Argentina
Brief: Shenzhen Hepalink Pharmaceutical Says H1710 Injection Received Approval For From NMPA